Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 5/20 | 0.48 |
| ▸ | MMP1 | P03956 | 4/20 | 0.48 |
| ▸ | MMP2 | P08253 | 4/20 | 0.48 |
| ▸ | MMP8 | P22894 | 4/20 | 0.48 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55573 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL25730272 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL29922190 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL29502115 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL57180 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL5432481 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL29381250 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL57241 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL22787577 | 1.00 | MEN1 (0.52) | MEN1ALDH1A1KMT2AEPHX2MMP9 | |
| SCHEMBL9680488 | 0.88 | EPHX2 (0.47) | MEN1ALDH1A1KMT2AEPHX2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3985007-A1 | TRIAZOLOPYRIMIDINE COMPOUND AND SALT, COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2022-04-20 | — | — | EP | disclosed |
| US-10442793-B2 | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines | JIANGSU HENGRUI MEDICINE CO., LTD (CN) | 2019-10-15 | — | — | US | disclosed |
| WO-2017063509-A1 | OXA SPIRO DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATIONS THEREOF IN MEDICINES | 江苏恒瑞医药股份有限公司 | 2017-04-20 | — | — | WO | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| EP-1968940-A1 | 3 , 5-SUBSTITUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | Novartis AG (CH) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442793-B2 | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines | OPRL1, OPRD1, OPRK1 | MEN1 2983/4885ALDH1A1 174/4885KMT2A 4345/4885 |
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | MEN1 228/4885ALDH1A1 3204/4885KMT2A 1997/4885 |
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | MEN1 2336/4885ALDH1A1 38/4885KMT2A 3129/4885 |
| US-20040204454-A1 | Lactam-containing cyclic diamines and derivatives as factor Xa inhibitors | PEPD, TFPI, F2 | MEN1 505/4885ALDH1A1 3153/4885KMT2A 1633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.